GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (FRA:2KZ) » Definitions » Additional Paid-In Capital

Kezar Life Sciences (FRA:2KZ) Additional Paid-In Capital : €498.48 Mil(As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences Additional Paid-In Capital?


Kezar Life Sciences's quarterly additional paid-in capital declined from Sep. 2023 (€501.40 Mil) to Dec. 2023 (€493.70 Mil) but then increased from Dec. 2023 (€493.70 Mil) to Mar. 2024 (€498.48 Mil).

Kezar Life Sciences's annual additional paid-in capital increased from Dec. 2021 (€334.32 Mil) to Dec. 2022 (€490.52 Mil) and increased from Dec. 2022 (€490.52 Mil) to Dec. 2023 (€493.70 Mil).


Kezar Life Sciences Additional Paid-In Capital Historical Data

The historical data trend for Kezar Life Sciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences Additional Paid-In Capital Chart

Kezar Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 146.26 219.55 334.32 490.52 493.70

Kezar Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 489.45 487.75 501.40 493.70 498.48

Kezar Life Sciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Kezar Life Sciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Kezar Life Sciences (FRA:2KZ) Business Description

Traded in Other Exchanges
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Kezar Life Sciences (FRA:2KZ) Headlines

No Headlines